Nicola Amodio collaborates with many scientific institutions in Italy (University of Calabria; University of Milan; Rizzoli Institute in Palermo; University of Genova; University of Brescia) and abroad (DFCI, Harvard Medical School; Washington University in St. Louis). He is consultant for Cellatrix, a biotech company in St. Louis (MO; USA), whose mission is the development of tools for the diagnosis and treatment of cancer. Nicola Amodio is the PI of a Research Unit within a MOH grant (2020-2022) at University of Catanzaro; since 2006, he has been Associate Investigator, and is currently PI, of grants funded by Italian Association for Cancer Research. He received a grant from Fondazione Lilli Funaro (Cosenza, I) in 2013 and a post-doctoral grant from Fondazione Umberto Veronesi (Milan, I) in 2016. He is member of the Italian Society for Cancer Research (SIC) and of Italian Society of Experimental Hematology (SIES) and Pathology (SIPMET). He delivered oral presentations at international and national scientific meetings. During his career, Nicola Amodio was awarded, for his scientific activity, by Fondazione Filli Funaro, the Italian Association for Cell Cultures (AICC), Soroptimist Club Varese, American Society of Haematology, Fondazione Umberto Veronesi, and other italian agencies. NA is currently Section editor in chief of “Cancers” journal and part of the Editorial Board of international peer-reviewed journals (Plos One, Non-Coding RNA, Frontiers in Pharmacology) Major focus of Dr. Nicola Amodio’s research has been the identification of novel molecularly-based therapies for cancers using integrated genomic/epigenomic analyses. Overall, NA research activity has provided novel insights into the molecular mechanisms of hematological malignancies, as multiple myeloma, and the framework for the development of innovative anti-cancer therapeutics, using non-coding RNA- targeting oligonucleotides and small molecules. Nicola Amodio’s studies have led to the identification of novel cancer vulnerabilities, including non-coding RNAs and transcription factors, with diagnostic and therapeutic potential; his studies have been highly cited and discussed by journal editorials, and have provided the molecular rationale for ongoing clinical trials in Italian and US institutions using small molecules and microRNA antagonists to treat hematological malignancies.